Back to search

United Kingdom· GB-APID-31261011000001102

Uronefrex 250mg capsules

A acetohydroxamic acid product containing acetohydroxamic acid, registered in United Kingdom by Imported (Spain). The same ATC class is registered in 2 of our 19 countries.

ATC G04BX03

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedUronefrex 250mg capsulesATCG04BX03REGISTER NO.GB-APID-3126101100000…PACKS LISTED0CHECKEDSeptember 13, 2026

Where it is registered

Acetohydroxamic acid is registered in 2 of 19 countries.

Countries holding a registration under ATC G04BX03 (acetohydroxamic acid), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 1 of them publish a price we can compare per daily dose

Acetohydroxamic acid · ATC G04BX03

2 / 19 countries

  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Acetohydroxamic acid
Manufacturer
Imported (Spain)
Country
United Kingdom (GB)
ATC code
G04BX03
ATC class
Acetohydroxamic acid
Defined daily dose
0.75 g, O
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

9 interactions on record for acetohydroxamic acid.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Acetohydroxamic acid · interactions on record

9 records

  • 2 severe
  • 7 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • CladribineL04AA40severe
  • AlemtuzumabL01XC04moderate
  • Omacetaxine mepesuccinateL01XX40moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Acetohydroxamic acid in 2 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All acetohydroxamic acid products

Authorised across Europe · EMA

The same active substance is authorised in 1 EEA country. Names it is sold under:

  • Spain · Uronefrex

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e1331724-4f8e-4f13-b8ee-41864add8c7a
GET /v1/drugs/e1331724-4f8e-4f13-b8ee-41864add8c7a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "31261011000001102",
  "desc": "Uronefrex 250mg capsules (Imported (Spain))",
  "form": "Oral capsule",
  "vpid": "22069911000001109",
  "source": "dmd",
  "vtm_id": "774419009",
  "strength": "250 mg",
  "substance": "Acetohydroxamic acid",
  "ingredient": "Acetohydroxamic acid",
  "supplier_code": "11821211000001109"
}

See everything about acetohydroxamic acid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.